An observational study in Breast Neoplasms, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-03.
Sponsored by Xiangya Hospital of Central South University · Observational
In this trial, we plan to construct a patient-derived organoid (PDO) model using fresh tumor tissue samples. Taking the relevant data of drug efficacy of breast cancer organoids as an example, it is shown that organoids may provide predictive information for drug sensitivity and may improve the therapeutic effect of advanced tumors. In this way, we aim to verify the effectiveness, feasibility and consistency of the PDO model in predicting treatment, and establish an evaluation system for treatment plans to help precision treatment of breast cancer.
This study is a prospective, observational clinical research focusing on the drug sensitivity of patient-derived organoid (PDO) models, aiming to evaluate the consistency between the drug sensitivity of PDO models and the efficacy of selected clinical regimens.
(3) Exploratory endpoints: 1. To conduct peripheral blood mononuclear cell (PBMC) isolation tests and RNA sequencing (RNA seq) for the included subjects, analyze the potential reasons for the differences in the consistency of PDO's predicted efficacy, and explore the underlying mechanisms.
(III) Research Contents:
3.1 Establishment of a PDO culture system suitable for breast cancer This study will use the hanging drop method organoid culture system, which can better preserve the tumor microenvironment of tumor cells, for the experiment. Breast cancer puncture samples obtained through informed consent will be digested into single-cell suspensions for organoid culture. Successfully cultured organoids will be collected for PBMC and RNA seq detection to assess the consistency of organoid tissue characteristics with those of the patient's pathological tissue and the infiltration of immune cells and drug penetration in the hanging drop method organoids. In this way, we will establish that the hanging drop method organoids reproduce the histological characteristics and marker expression of the original tumor tissue.
3.2 Detection of patient sensitivity to different induction chemotherapy regimens using the PDO system Based on the PDO organoid culture system established above, we will culture organoids from samples that meet the inclusion criteria. Once the culture is successful, the organoids will be immediately treated with multiple chemotherapy regimens and the treatment regimens that the patients will receive. The cell viability of the organoids will be measured as an indicator of organoid survival. By directly comparing with the CellTiter-Glo3D cell viability assay, the sensitivity of the organoids to different chemotherapy regimens will be statistically analyzed, and the most sensitive treatment regimen will be screened out.
3.3 Collection of clinical data and consistency analysis of drug sensitivity test results This trial aims to complete drug sensitivity tests on 30 samples. According to the actual clinical treatment regimens, the data of the 30 samples will be divided into two groups: consistent or inconsistent with the best drug sensitivity test regimen. The differences in objective response rate and disease control rate between the two groups will be statistically analyzed. At the same time, based on the drug sensitivity screening results, the consistency of clinical efficacy indicators of these patients will be statistically analyzed. In terms of prognosis, the differences in overall survival and progression-free survival between the two groups will be statistically analyzed.
12,543 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 30 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Xiangya Hospital of Central South University is the lead sponsor of 170 studies on the registry; 76 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with breast cancer
Inclusion and Exclusion Criteria for Early - stage Breast Cancer 1.1 Inclusion Criteria Age between 18 and 70 years old, regardless of gender. ECOG score: 0 - 1. Clinically diagnosed or pathologically confirmed as breast cancer. TNM stage is T2 - 3 and Nx, and is currently receiving or planning to receive subsequent neoadjuvant therapy (including but not limited to chemotherapy, targeted therapy, endocrine therapy, etc.).
According to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), there is at least one measurable lesion; the expected survival time is ≥ 12 weeks.
The subject must recover from all toxicities caused by previous treatments (recovery to ≤ grade 1, evaluated based on CTCAE 5.0, or meet the inclusion criteria of the protocol), except for alopecia, vitiligo, or hypothyroidism that remains stable after hormone replacement therapy. (Note: For subjects with some chronic and stable grade 2 toxicities that the researcher deems related to previous anti - tumor treatments (such as chemotherapy - induced neuropathy), a decision on whether to include the subject in this study will be made after discussion with the medical monitor.) For female subjects with child - bearing potential and male subjects whose partners have reproductive potential, effective medical contraceptive measures should be taken during the research treatment period and within 6 months after the end of drug administration.
Voluntarily sign the informed consent form, and be willing and able to comply with the follow - up, treatment, laboratory tests, and other research requirements specified in the research schedule.
1.2 Exclusion Criteria Central nervous system (CNS) metastasis or carcinomatous meningitis. Bilateral breast cancer. History of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). History of invasive breast cancer or metastatic breast cancer. Arterial or venous thrombosis events, such as deep vein thrombosis and pulmonary embolism, occurred within 3 months before randomization.
Positive human immunodeficiency virus (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
Other serious diseases that are judged to potentially affect follow - up and short - term survival of the patient.
Inability to swallow, chronic diarrhea, and intestinal obstruction, with various factors affecting drug intake and absorption.
Known allergy to the potentially used treatment drugs. Adverse reactions of grade ≥ 1 that are still ongoing due to previous treatments. Exceptions are alopecia or cases that the researcher deems should not be excluded. Such cases should be clearly recorded in the investigator's notes.
Female patients who are pregnant, breastfeeding, or planning to become pregnant during the study period (pregnancy tests should be considered for sexually active women of child - bearing age).
Having had other malignancies within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin.
Urinalysis shows urine protein ≥ 2+ or confirmed 24 - hour urine protein quantification > 1.0g; presence of any autoimmune diseases that still require treatment or a history of autoimmune diseases, excluding hypothyroidism caused by autoimmune thyroiditis that only requires hormone replacement therapy and type 1 diabetes with controllable and stable blood sugar.
Patients with hypertension that cannot be well - controlled with a single antihypertensive drug (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg); history of unstable angina pectoris; newly diagnosed angina pectoris within 3 months before screening or myocardial infarction event within 6 months before screening; arrhythmia (including QTcF: ≥ 450 ms for men and ≥ 470 ms for women) requiring long - term use of anti - arrhythmic drugs and New York Heart Association class ≥ II heart failure.
Other situations that researchers evaluate as potentially endangering the patient's safety or having poor compliance, such as having serious diseases (including mental diseases), severely abnormal test results, and other high - risk factors in the family or society.
Inclusion and Exclusion Criteria for Advanced - stage Breast Cancer 2.1 Inclusion Criteria Age between 18 and 70 years old, both men and women are eligible. ECOG score: 0 - 1. Clinically or pathologically clearly diagnosed as advanced - stage breast cancer, regardless of molecular subtype.
Currently receiving or planning to receive anti - tumor drug treatment, regardless of the number of treatment lines.
According to the Response Evaluation Criteria in Solid Tumors (RECIST1.1), there is at least one measurable lesion; the expected survival time is ≥ 12 weeks.
The subject must recover from all toxicities caused by previous treatments (recovery to ≤ grade 1, evaluated based on CTCAE5.0, or meet the inclusion criteria of the protocol), except for alopecia, vitiligo, or hypothyroidism that remains stable after hormone replacement therapy.
(Note: For subjects with some chronic and stable grade 2 toxicities that the researcher deems related to previous anti - tumor treatments (such as chemotherapy - induced neuropathy), a decision on whether to include the subject in this study will be made after discussion with the medical monitor.) For female subjects with child - bearing potential and male subjects whose partners have reproductive potential, effective medical contraceptive measures should be taken during the research treatment period and within 6 months after the end of drug administration.
Voluntarily sign the informed consent form, and be willing and able to comply with the follow - up, treatment, laboratory tests, and other research requirements specified in the research schedule.
2.2 Exclusion Criteria Central nervous system (CNS) metastasis or carcinomatous meningitis. History of gastrointestinal perforation or fistula within half a year before medication or having a high bleeding risk.
Positive human immunodeficiency virus (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
Other serious diseases that are judged to potentially affect follow - up and may lead to short - term survival of the patient.
Inability to swallow, chronic diarrhea, and intestinal obstruction, with various factors affecting drug intake and absorption.
Known allergy to the potentially used treatment drugs. Adverse reactions of grade ≥ 1 that are still ongoing due to previous treatments. Exceptions are alopecia or cases that the researcher deems should not be excluded. Such cases should be clearly recorded in the investigator's notes.
Pregnant or breastfeeding women (pregnancy tests should be considered for sexually active women of child - bearing age).
Having had other malignancies within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin.
Occurrence of abdominal fistula, gastrointestinal perforation, or abdominal abscess within 28 days before participating in this study.
Urinalysis shows urine protein ≥ ++ or confirmed 24 - hour urine protein quantification > 1.0g.
Patients with hypertension that cannot be reduced to the normal range with antihypertensive drugs (systolic blood pressure > 140mmHg, diastolic blood pressure > 90mmHg).
Other situations that researchers evaluate as potentially endangering the patient's safety or having poor compliance, such as having serious diseases (including mental diseases), severely abnormal test results, and other high - risk factors in the family or society.
If a test sample meets any of the following criteria, it must be excluded:
Samples with unsuccessful PDO culture. Samples contaminated or failed due to improper operation during the test. Samples with lost data. Samples from patients who withdraw their informed consent and do not want to leave their samples.
Objective Response Rate（ORR).
The proportion defined as subjects with complete remission (CR) and partial remission (PR) among all subjects.
Time frame: 2024-06-02 to 2026-05-31
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiangya Hospital of Central South University